Abstract: Disclosed herein are compositions and methods of treating a spinal cord injury and improving spinal cord function. Also disclosed are compositions and methods of stimulating regeneration, promoting glial cell proliferation, promoting axonal tract regeneration, triggering neurite outgrowth, and triggering neuron formation in injured and/or damaged spinal cord tissue.

Abstract: Disclosed herein are compositions for and methods of performing a multi-omics assay comprising analyzing chromatin structure and function and analyzing the transcriptome using the same population of cells. Disclosed herein are compositions for and methods of performing a high-throughput chromosome conformation capture on accessible DNA and mRNA-Seq co-assay (HiCAR).

Abstract: An ultrasound system is disclosed. Embodiments in accordance with the present invention include a transducer configured to acquire pulse-echo data at each transmit frequency bandwidth of interest. In addition, a bandpass filter is configured to receive a signal of the pulse-echo data, wherein the signal is bandpass-filtered over a plurality of frequencies. Further, a processor is configured to calculate a spatial coherence of the bandpass-filtered signal. The spatial coherence of the signal is calculated in a spatial domain or a frequency domain. The spatial coherence is used to predict target conspicuity. The processor selects a preferred frequency based on and, preferably, to realize, the target conspicuity.

Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.

Abstract: Disclosed herein are transcription activator-like effector nuclease (TALEN)-related compositions and methods of using said TALENs for correcting mutant genes.

Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

Abstract: A system for delivering electrical pulse stimulation to a subject includes a remote control device configured to at least intermittently transmit temporal pulse pattern programming and a stimulation device comprising a control interface, at least one electrode in electrical communication with the control interface, and an input device in at least intermittent communication with the remote control device to receive the temporal pulse pattern programming. The stimulation device is configured to deliver electrical pulse stimulation to a subject via the at least one electrode according to the temporal pulse pattern programming.

Abstract: The present disclosure provides compositions and methods for the treatment of pathogen-induced and/or chemical-induced lung injury, for regenerating lung epithelial cells following lung injury, for treating cancer, and for sensitizing a subject suffering from cancer to a chemotherapeutic agent.

Abstract: A transducer array includes at least one annular shear wave generation transducer that defines an interior area, the at least one annular shear wave generation transducer being configured to generate a shear wave excitation to a region of interest such that the shear wave excitation excites at least a part of a corresponding cylindrical portion of the region of interest and shear waves propagating from the cylindrical portion of the region of interest constructively interfere in an interior region of the cylindrical portion of the region of interest; and at least one tracking transducer positioned in the interior area of the at least one annular shear wave generation transducer, the at least one tracking transducer being configured to detect a shear wave in the interior region of the region of interest.

Abstract: In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelope selections from individual CH505, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Abstract: Disclosed herein are methods are compositions and methods for enhancing regeneration in stressed damaged, and/or injured tissues.

Abstract: Systems and methods for stimulation of neurological tissue generate stimulation trains with temporal patterns of stimulation, in which the interval between electrical pulses (the inter-pulse intervals) changes or varies over time. Compared to conventional continuous, high rate pulse trains having regular (i.e., constant) inter-pulse intervals, the non-regular (i.e., not constant) pulse patterns or trains that embody features of the invention provide a lower average frequency.

Abstract: Provided herein are compositions and methods for detection of N6-methyladenosine (m6A) in ribonucleic acid (RNA). The provided compositions include fusion proteins that can be used to edit RNA and detect m6A residues. Also provided are nucleic acids, vectors, constructs, host cells, and transgenic animals that encode or express such fusions proteins.

Abstract: Disclosed herein are compositions and methods for treating uterine fibroids in vivo, and methods of reducing symptoms associated with uterine fibroids, including pain, bleeding and infertility. The disclosed compositions comprise collagenase in an amount effective to cause shrinkage and/or reduce stiffness of uterine fibroids.

Abstract: A method of using at least one implantable mesh extension for repairing a tissue defect or reconstructing tissue, wherein the mesh extension is comprised of a mesh having a width and a length extending between a first end and a second end, includes passing the first end of the mesh extension through tissue adjacent to the tissue defect or tissue to be reconstructed at least once and then passing the first end of the mesh extension through a portion of the mesh. The mesh extension is then pulled to create a first self-locking stitch to anchor the mesh extension to the adjacent tissue so as to immediately resist high tension.

Abstract: The disclosure is directed to a G-protein coupled receptor complex. The complex includes (i) a chimeric G protein-coupled receptor (GPCR) comprising a non-native amino acid sequence located within the C-terminus of the GPCR and a synthetic phosphopeptide ligated to the non-native amino acid sequence; and (ii) a ?-arrestin (?arr) protein bound to the C-terminus of the GPCR. The disclosure also provides an in vitro method for producing the aforementioned complex, as well as methods for identifying compounds or ligands which bind to and modulate the activity of the complex. Positive allosteric modulators of the ?2 adrenergic receptor identified by screening a DNA-encoded library potentiate the activity of ?2 agonists and have application in the treatment of obstructive airway disease, bronchospasm, or pre-term labor.

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-switching oligonucleotides to treat cancer, specifically castrate resistant prostate cancer.

Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.